{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T10:48:02Z","timestamp":1659610082177},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T00:00:00Z","timestamp":1395705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T00:00:00Z","timestamp":1395705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1038\/pcan.2014.12","type":"journal-article","created":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T11:32:22Z","timestamp":1395747142000},"page":"112-118","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel bone-targeting agents in prostate cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"C","family":"Albany","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N M","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,25]]},"reference":[{"key":"BFpcan201412_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11\u201330.","journal-title":"CA Cancer J Clin"},{"key":"BFpcan201412_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/sj.pcan.4500705","volume":"7","author":"JP Coxon","year":"2004","unstructured":"Coxon JP, Oades GM, Colston KW, Kirby RS . Advances in the use of bisphosphonates in the prostate cancer setting. Prostate Cancer Prostatic Dis 2004; 7: 99\u2013104.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan201412_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1046\/j.1464-410X.1997.00237.x","volume":"80","author":"R Nemoto","year":"1997","unstructured":"Nemoto R, Nakamura I, Nishijima Y, Shiobara K, Shimizu M, Takehara T et al. Serum pyridinoline crosslinks as markers of tumour-induced bone resorption. Br J Urol 1997; 80: 274\u2013280.","journal-title":"Br J Urol"},{"key":"BFpcan201412_CR4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0022-5347(01)65196-6","volume":"157","author":"H Maeda","year":"1997","unstructured":"Maeda H, Koizumi M, Yoshimura K, Yamauchi T, Kawai T, Ogata E . Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol 1997; 157: 539\u2013543.","journal-title":"J Urol"},{"key":"BFpcan201412_CR5","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/JCO.2001.19.15.3562","volume":"19","author":"GD Roodman","year":"2001","unstructured":"Roodman GD . Biology of osteoclast activation in cancer. J Clin Oncol 2001; 19: 3562\u20133571.","journal-title":"J Clin Oncol"},{"key":"BFpcan201412_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ucl.2004.02.002","volume":"31","author":"MG Oefelein","year":"2004","unstructured":"Oefelein MG, Resnick MI . The impact of osteoporosis in men treated for prostate cancer. Urol Clin North Am 2004; 31: 313\u2013319.","journal-title":"Urol Clin North Am"},{"key":"BFpcan201412_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","volume":"20","author":"T Suda","year":"1999","unstructured":"Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ . Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345\u2013357.","journal-title":"Endocr Rev"},{"key":"BFpcan201412_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nm1593","volume":"13","author":"M Zaidi","year":"2007","unstructured":"Zaidi M . Skeletal remodeling in health and disease. Nat Med 2007; 13: 791\u2013801.","journal-title":"Nat Med"},{"key":"BFpcan201412_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jama.292.4.490","volume":"292","author":"LC Hofbauer","year":"2004","unstructured":"Hofbauer LC, Schoppet M . Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases. JAMA 2004; 292: 490\u2013495.","journal-title":"JAMA"},{"key":"BFpcan201412_CR10","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1017\/S1462399408000616","volume":"10","author":"GA Clines","year":"2008","unstructured":"Clines GA, Guise TA . Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 2008; 10: e7.","journal-title":"Expert Rev Mol Med"},{"key":"BFpcan201412_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/pcan.2009.50","volume":"13","author":"PJ Saylor","year":"2010","unstructured":"Saylor PJ, Smith MR . Bone health and prostate cancer. Prostate Cancer Prostatic Dis 2010; 13: 20\u201327.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan201412_CR12","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","volume":"169","author":"MR Smith","year":"2003","unstructured":"Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N . Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008\u20132012.","journal-title":"J Urol"},{"key":"BFpcan201412_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1464-410X.2007.06853.x","volume":"100","author":"CW Ryan","year":"2007","unstructured":"Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO et al. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int 2007; 100: 70\u201375.","journal-title":"BJU Int"},{"key":"BFpcan201412_CR14","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","volume":"25","author":"MD Michaelson","year":"2007","unstructured":"Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038\u20131042.","journal-title":"J Clin Oncol"},{"key":"BFpcan201412_CR15","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458\u20131468.","journal-title":"J Natl Cancer Inst"},{"key":"BFpcan201412_CR16","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879\u2013882.","journal-title":"J Natl Cancer Inst"},{"key":"BFpcan201412_CR17","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hern\u00e1ndez Toriz N, Feldman R, Tammela TL, Saad F et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745\u2013755.","journal-title":"N Engl J Med"},{"key":"BFpcan201412_CR18","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1016\/j.juro.2009.08.048","volume":"182","author":"MR Smith","year":"2009","unstructured":"Smith MR, Saad F, Egerdie B, Szwedowski M, Tammela TL, Ke C et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 2009; 182: 2670\u20132675.","journal-title":"J Urol"},{"key":"BFpcan201412_CR19","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813\u2013822.","journal-title":"Lancet"},{"key":"BFpcan201412_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","volume":"379","author":"MR Smith","year":"2011","unstructured":"Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2011; 379: 39\u201346.","journal-title":"Lancet"},{"issue":"20 Pt 2","key":"BFpcan201412_CR21","doi-asserted-by":"publisher","first-page":"6296s","DOI":"10.1158\/1078-0432.CCR-06-0929","volume":"12","author":"MA Carducci","year":"2006","unstructured":"Carducci MA, Jimeno A . Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006; 12 (20 Pt 2): 6296s\u20136300s.","journal-title":"Clin Cancer Res"},{"key":"BFpcan201412_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/cncr.21642","volume":"106","author":"S Basaria","year":"2006","unstructured":"Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS . Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006; 106: 581\u2013588.","journal-title":"Cancer"},{"key":"BFpcan201412_CR23","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1093\/annonc\/mdq050","volume":"21","author":"MD Galsky","year":"2010","unstructured":"Galsky MD, Vogelzang NJ . Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 2010; 21: 2135\u20132144.","journal-title":"Ann Oncol"},{"key":"BFpcan201412_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1200\/JCO.2003.04.176","volume":"21","author":"MA Carducci","year":"2003","unstructured":"Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21: 679\u2013689.","journal-title":"J Clin Oncol"},{"key":"BFpcan201412_CR25","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/cncr.22996","volume":"110","author":"MA Carducci","year":"2007","unstructured":"Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110: 1959\u20131966.","journal-title":"Cancer"},{"key":"BFpcan201412_CR26","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/cncr.23864","volume":"113","author":"JB Nelson","year":"2008","unstructured":"Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008; 113: 2478\u20132487.","journal-title":"Cancer"},{"key":"BFpcan201412_CR27","doi-asserted-by":"crossref","unstructured":"Quinn David I, Tangen Catherine M, Hussain Maha, Lara Primo N, Goldkorn Amir, Garzotto Mark et al. SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC). J Clin Oncol 2012; (suppl; abstr 4511).","DOI":"10.1200\/jco.2012.30.15_suppl.4511"},{"key":"BFpcan201412_CR28","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.eururo.2008.11.002","volume":"55","author":"ND James","year":"2009","unstructured":"James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009; 55: 1112\u20131123.","journal-title":"Eur Urol"},{"key":"BFpcan201412_CR29","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1200\/JCO.2012.46.4149","volume":"31","author":"KS Fizazi","year":"2013","unstructured":"Fizazi KS, Higano CS, Nelson JB, Gleave M, Miller K, Morris T et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2013; 31: 1740\u20131747.","journal-title":"J Clin Oncol"},{"key":"BFpcan201412_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/pcan.2013.2","volume":"16","author":"K Miller","year":"2013","unstructured":"Miller K, Moul JW, Gleave M, Fizazi K, Nelson JB, Morris T et al. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2013; 16: 187\u2013192.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan201412_CR31","first-page":"1370","volume":"62","author":"S Raghow","year":"2002","unstructured":"Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS . Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 2002; 62: 1370\u20131376.","journal-title":"Cancer Res"},{"issue":"1 Suppl","key":"BFpcan201412_CR32","first-page":"S45","volume":"189","author":"MR Smith","year":"2013","unstructured":"Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 2013; 189 (1 Suppl): S45\u2013S50.","journal-title":"J Urol"},{"key":"BFpcan201412_CR33","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S1470-2045(05)70206-0","volume":"6","author":"IG Finlay","year":"2005","unstructured":"Finlay IG, Mason MD, Shelley M . Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005; 6: 392\u2013400.","journal-title":"Lancet Oncol"},{"key":"BFpcan201412_CR34","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","volume":"8","author":"S Nilsson","year":"2007","unstructured":"Nilsson S, Franz\u00e9n L, Parker C, Tyrrell C, Blom R, Tennvall J et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8: 587\u2013594.","journal-title":"Lancet Oncol"},{"key":"BFpcan201412_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/107327481201900208","volume":"19","author":"M Tomblyn","year":"2012","unstructured":"Tomblyn M . The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases. Cancer Control 2012; 19: 137\u2013144.","journal-title":"Cancer Control"},{"key":"BFpcan201412_CR36","first-page":"330","volume":"26","author":"PJ Cheetham","year":"2012","unstructured":"Cheetham PJ, Petrylak DP . Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection. Oncology (Williston Park) 2012; 26: 330\u2013337 341.","journal-title":"Oncology (Williston Park)"},{"key":"BFpcan201412_CR37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","volume":"8","author":"S Nilsson","year":"2007","unstructured":"Nilsson S, Franz\u00e9n L, Parker C, Tyrrell C, Blom R, Tennvall J et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8: 587\u2013594.","journal-title":"Lancet Oncol"},{"key":"BFpcan201412_CR38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213\u2013223.","journal-title":"N Engl J Med"},{"key":"BFpcan201412_CR39","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1158\/1078-0432.CCR-08-1306","volume":"15","author":"JP Eder","year":"2009","unstructured":"Eder JP, Vande Woude GF, Boerner SA, LoRusso PM . Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15: 2207\u20132214.","journal-title":"Clin Cancer Res"},{"key":"BFpcan201412_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1535-6108(03)00085-0","volume":"3","author":"S Pennacchietti","year":"2003","unstructured":"Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM . Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3: 347\u2013361.","journal-title":"Cancer Cell"},{"key":"BFpcan201412_CR41","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/S0090-4295(02)01954-4","volume":"60","author":"BS Knudsen","year":"2002","unstructured":"Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002; 60: 1113\u20131117.","journal-title":"Urology"},{"key":"BFpcan201412_CR42","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/1471-2407-10-556","volume":"10","author":"WH Tu","year":"2010","unstructured":"Tu WH, Zhu C, Clark C, Christensen JG, Sun Z . Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer 2010; 10: 556.","journal-title":"BMC Cancer"},{"key":"BFpcan201412_CR43","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10: 2298\u20132308.","journal-title":"Mol Cancer Ther"},{"key":"BFpcan201412_CR44","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1200\/JCO.2012.45.0494","volume":"31","author":"DC Smith","year":"2013","unstructured":"Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013; 31: 412\u2013419.","journal-title":"J Clin Oncol"},{"key":"BFpcan201412_CR45","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1093\/annonc\/mdm086","volume":"18","author":"K Fizazi","year":"2007","unstructured":"Fizazi K . The role of Src in prostate cancer. Ann Oncol 2007; 18: 1765\u20131773.","journal-title":"Ann Oncol"},{"key":"BFpcan201412_CR46","doi-asserted-by":"publisher","first-page":"9185","DOI":"10.1158\/0008-5472.CAN-05-1731","volume":"65","author":"S Nam","year":"2005","unstructured":"Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65: 9185\u20139189.","journal-title":"Cancer Res"},{"key":"BFpcan201412_CR47","doi-asserted-by":"publisher","first-page":"7421","DOI":"10.1158\/1078-0432.CCR-09-1691","volume":"15","author":"EY Yu","year":"2009","unstructured":"Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15: 7421\u20137428.","journal-title":"Clin Cancer Res"},{"key":"BFpcan201412_CR48","doi-asserted-by":"crossref","unstructured":"Araujo John C, Trudel Geralyn C, Saad Fred, Armstrong Andrew J, Yu Evan Y, Bellmunt Joaquim et al. Overall survival (OS) and safety of dasatinib\/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized phase III READY trial. J Clin Oncol 2013; 31, (suppl 6; abstr LBA8).","DOI":"10.1200\/jco.2013.31.6_suppl.lba8"},{"key":"BFpcan201412_CR49","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995\u20132005.","journal-title":"N Engl J Med"},{"key":"BFpcan201412_CR50","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","volume":"13","author":"CJ Logothetis","year":"2012","unstructured":"Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012; 13: 1210\u20131217.","journal-title":"Lancet Oncol"},{"key":"BFpcan201412_CR51","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187\u20131197.","journal-title":"N Engl J Med"},{"key":"BFpcan201412_CR52","doi-asserted-by":"crossref","unstructured":"Fizazi K, HI Scher, Saad F et al. Impact of Enzalutamide, an androgen receptor signaling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study. Ann Oncol 2012; 23, (suppl 9; abstract 8960).","DOI":"10.1016\/S0923-7534(20)33481-5"},{"key":"BFpcan201412_CR53","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL . Osteoclast differentiation and activation. Nature 2003; 423: 337\u2013342.","journal-title":"Nature"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan201412.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201412","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201412.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:38:45Z","timestamp":1648676325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,25]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["BFpcan201412"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2014.12","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,25]]},"assertion":[{"value":"30 October 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}